Jane Robertson

2.8k total citations
57 papers, 2.0k citations indexed

About

Jane Robertson is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Jane Robertson has authored 57 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 42 papers in Oncology, 18 papers in Molecular Biology and 17 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Jane Robertson's work include Colorectal Cancer Treatments and Studies (22 papers), Cancer Treatment and Pharmacology (15 papers) and PARP inhibition in cancer therapy (10 papers). Jane Robertson is often cited by papers focused on Colorectal Cancer Treatments and Studies (22 papers), Cancer Treatment and Pharmacology (15 papers) and PARP inhibition in cancer therapy (10 papers). Jane Robertson collaborates with scholars based in United Kingdom, United States and Canada. Jane Robertson's co-authors include Juliane M. Jürgensmeier, M Dougal, Thomas A. Puchalski, Hans‐Joachim Schmoll, Anitra Fielding, O. Saunders, Clemens Unger, Joachim Drevs, Helen Mann and Tony W. Ho and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cell Metabolism.

In The Last Decade

Jane Robertson

57 papers receiving 2.0k citations

Peers

Countries citing papers authored by Jane Robertson

Since Specialization

Citations

This map shows the geographic impact of Jane Robertson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jane Robertson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jane Robertson more than expected).

Fields of papers citing papers by Jane Robertson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jane Robertson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jane Robertson. The network helps show where Jane Robertson may publish in the future.

Co-authorship network of co-authors of Jane Robertson

This figure shows the co-authorship network connecting the top 25 collaborators of Jane Robertson. A scholar is included among the top collaborators of Jane Robertson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jane Robertson. Jane Robertson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	37P Phase II results of the porcupine (PORCN) inhibitor zamaporvint (RXC004) in genetically selected microsatellite stable colorectal cancer patients 2024 ·Annals of Oncology ·Natalie Cook, (unknown), Mark Saunders, Scott Kopetz, (unknown), (unknown), Bert H. O’Neil, (unknown), J. Graham, Joan Maurel, T.W. Kim, Ian Chau, Shamim Saleha, Louise Goodwin, David M. Wilson, Jane Robertson, (unknown), (unknown), Simon A. Woodcock, Van K. Morris	2
2	222P Therapeutic opportunities for porcupine inhibition in gastrointestinal cancer 2023 ·Annals of Oncology ·Natalie Cook, Wu Su, (unknown), (unknown), Jane Robertson, Simon A. Woodcock	1
3	Adoptive cell therapy with tumour-infiltrating lymphocytes: the emerging importance of clonal neoantigen targets for next-generation products in non-small cell lung cancer 2019 ·Immuno-Oncology Technology ·Jane Robertson, Max Salm, Markus Dangl	22
4	Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes 2018 ·British Journal of Cancer ·Darren Hodgson, Brian Dougherty, Zhongwu Lai, Anitra Fielding, Lynda Grinsted, Stuart Spencer, Mark J. O’Connor, Tony W. Ho, Jane Robertson, Jerry S. Lanchbury, Kirsten M. Timms, Alexander Gutin, Maria Orr, Helen Jones, C. Blake Gilks, Chris Womack, Charlie Gourley, Jonathan A. Ledermann, J. Carl Barrett	167
5	Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation: a multistudy analysis of response rates and safety 2016 ·Annals of Oncology ·Ursula A. Matulonis, Richard T. Penson, S. M. Domchek, Bella Kaufman, Ronnie Shapira‐Frommer, M. William Audeh, S.B. Kaye, L. Rhoda Molife, Karen A. Gelmon, Jane Robertson, Helen Mann, Tony W. Ho, Robert L. Coleman	125
6	Leptin, BMI, and a Metabolic Gene Expression Signature Associated with Clinical Outcome to VEGF Inhibition in Colorectal Cancer 2015 ·Cell Metabolism ·Aurélien Pommier, Matthew R. Farren, Bhavika Patel, Mark Wappett, Filippos Michopoulos, Neil R. Smith, Jane Kendrew, (unknown), R. Huby, Catherine A. Eberlein, (unknown), Christopher J. Womack, Paul Smith, Jane Robertson, Shethah Morgan, Susan E. Critchlow, Simon T. Barry	15
7	Serum protein profiling reveals baseline and pharmacodynamic biomarker signatures associated with clinical outcome in mCRC patients treated with chemotherapy ± cediranib 2014 ·British Journal of Cancer ·Aurélien Pommier, Robert A. Shaw, Stuart Spencer, Shethah Morgan, Paulo M. Hoff, Jane Robertson, Simon T. Barry, Juliane M. Jürgensmeier	13
8	Correlation of Lactate Dehydrogenase Isoenzyme Profile With Outcome in Patients With Advanced Colorectal Cancer Treated With Chemotherapy and Bevacizumab or Cediranib: Retrospective Analysis of the HORIZON I Study 2013 ·Clinical Colorectal Cancer ·Jair Bar, Stuart Spencer, Shethah Morgan, Laura Brooks, David Cunningham, Jane Robertson, Juliane M. Jürgensmeier, Glenwood D. Goss	23
9	Prognostic and predictive value of VEGF, sVEGFR-2 and CEA in mCRC studies comparing cediranib, bevacizumab and chemotherapy 2013 ·British Journal of Cancer ·Juliane M. Jürgensmeier, Hans‐Joachim Schmoll, Jane Robertson, Laura Brooks, Maria Taboada, Shethah Morgan, David M. Wilson, Paulo M. Hoff	50
10	KRAS mutations are associated with inferior clinical outcome in patients with metastatic colorectal cancer, but are not predictive for benefit with cediranib 2013 ·European Journal of Cancer ·John Smith, Laura Brooks, Paulo M. Hoff, Gael McWalter, Simon Dearden, Shethah Morgan, David M. Wilson, Jane Robertson, Juliane M. Jürgensmeier	14
11	Prognostic/predictive value of 207 serum factors in colorectal cancer treated with cediranib and/or chemotherapy 2013 ·British Journal of Cancer ·Stuart Spencer, Aurélien Pommier, Shethah Morgan, Simon T. Barry, Jane Robertson, Paulo M. Hoff, Juliane M. Jürgensmeier	21
12	Cediranib with mFOLFOX6 vs bevacizumab with mFOLFOX6 in previously treated metastatic colorectal cancer 2013 ·British Journal of Cancer ·(unknown), David Cunningham, Ralph Wong, Geert D’Haens, J-Y Douillard, Jane Robertson, A Stone, Eric Van Cutsem	38
13	Cediranib Plus FOLFOX/CAPOX Versus Placebo Plus FOLFOX/CAPOX in Patients With Previously Untreated Metastatic Colorectal Cancer: A Randomized, Double-Blind, Phase III Study (HORIZON II) 2012 ·Journal of Clinical Oncology ·Paulo M. Hoff, Andreas Hochhaus, Bernhard C. Pestalozzi, Niall C. Tebbutt, Jin Li, Tae Won Kim, Krassimir Koynov, G. Kurteva, Tamás Pintér, Ying Cheng, Brigitte Van Eyll, Laura A. Pike, Anitra Fielding, Jane Robertson, Mark Saunders	112
14	Cediranib With mFOLFOX6 Versus Bevacizumab With mFOLFOX6 As First-Line Treatment for Patients With Advanced Colorectal Cancer: A Double-Blind, Randomized Phase III Study (HORIZON III) 2012 ·Journal of Clinical Oncology ·Hans‐Joachim Schmoll, David Cunningham, Alberto Sobrero, Christos S. Karapetis, Philippe Rougier, Sheryl Koski, Ilona Kocáková, Igor Bondarenko, G. Bodoky, Paul N. Mainwaring, Ramón Salazar, Peter Barker, Bijoyesh Mookerjee, Jane Robertson, Eric Van Cutsem	163
15	Phase I evaluation of cediranib, a selective VEGFR signalling inhibitor, in combination with gefitinib in patients with advanced tumours 2010 ·European Journal of Cancer ·Hester van Cruijsen, Emile E. Voest, Cornelis J.A. Punt, Klaas Hoekman, Petronella O. Witteveen, Martijn R. Meijerink, Thomas A. Puchalski, Jane Robertson, O. Saunders, Juliane M. Jürgensmeier, Carla M.L. van Herpen, Giuseppe Giaccone	47
16	An open-label, Phase I study of cediranib (RECENTIN™) in patients with acute myeloid leukemia 2009 ·Leukemia Research ·Walter Fiedler, Rolf M. Mesters, Michael Heuser, Gerhard Ehninger, Wolfgang E. Berdel, Ute Zirrgiebel, Jane Robertson, (unknown), Barbara Collins, Juliane M. Jürgensmeier, Hubert Serve	36
17	Telomerase Activity and Telomere Length in the Haemopoietic System: Changes with Aging, Disease, and Therapy 2000 ·Jane Robertson, Robert Wynn	3
18	Detection of hTERT protein by flow cytometry 2000 ·Leukemia ·Ased Ali, Rajesh Chopra, Jane Robertson, (unknown)	11
19	Immunogenicity of vaccination against influenza, Streptococcus pneumoniae and Haemophilus influenzae type B in patients with multiple myeloma 2000 ·British Journal of Cancer ·Jane Robertson, K.R. Nagesh, (unknown), M Dougal, Heather Anderson, Ken Mutton, Maria Zambon, J.H. Scarffe	139
20	Dynamics of telomere shortening in neutrophils and T lymphocytes during ageing and the relationship to skewed X chromosome inactivation patterns 2000 ·British Journal of Haematology ·Jane Robertson, Rosemary E. Gale, Robert Wynn, M Dougal, David C. Linch, Nydia G. Testa, Rajesh Chopra	82

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact